Alkem Laboratories Limited — Updates, 13-03-2025: Press Release

US FDA conducted a Bioresearch Monitoring (BIMO) inspection at Alkem Laboratories' Bioequivalence Center in Taloja, Maharashtra. The inspection occurred from 10th to 13th March, concluding with no Form 483 issued, which is a positive outcome indicating no significant compliance issues were found. This development suggests a favorable standing for Alkem's operations at this facility, potentially enhancing its reputation and operational continuity in the highly regulated pharmaceutical sector. Investors may view this as a signal of robust compliance practices, supporting a stable outlook for future operations.